sorafenib has been researched along with khellin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (khellin) | Trials (khellin) | Recent Studies (post-2010) (khellin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 4,757 | 193 | 1,727 |
| Protein | Taxonomy | sorafenib (IC50) | khellin (IC50) |
|---|---|---|---|
| Cytochrome P450 1A1 | Homo sapiens (human) | 4.02 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.04 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YL; Ding, X; Gao, Z; Gu, T; Liu, W; Qu, M; Wang, W; Wu, X; Xu, L; Zhang, W | 1 |
1 other study(ies) available for sorafenib and khellin
| Article | Year |
|---|---|
Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways.
Topics: Adult; Cell Cycle; Cell Movement; Cell Proliferation; Cells, Cultured; Female; Fibroblasts; Humans; Keloid; Male; Middle Aged; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sincalide; Smad Proteins; Sorafenib; Transforming Growth Factor beta; Young Adult | 2016 |